A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Advanced Solid Tumor Malignancies
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Histologically confirmed locally advanced or metastatic solid tumor malignancy other than clear cell renal cell carcinoma with progression on at least one prior systemic therapy and with evidence of SETD2 pathogenic mutation detected on CLIA certified NGS panel. or 2) Patients with histologically confirmed locally advanced or metastatic clear cell renal cell caricnoma (with clear cell component on pathology) progressed on at least one prior systemic therapy and with evidence of SETD2 pathogenic mutation detected on CLIA certified NGS panel.

You may not be eligible for this study if the following are true:

  • 1) Use of anti-cancer treatment drug = 21 days or 5 half-lives (whichever is shorter) prior to the first dose of AZD1775. 2) Unable to take oral medications. 3) Active CNS disease.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.